Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond Transition's control, adverse events that would require clinical trials to be prematurely terminated, clinical results that indicate continuing clinical and commercial pursuit of E1-I.N.T.(TM) is not advisable, the fact that the results from completed exploratory Phase IIa clinical trials are not always indicative of those seen in future clinical trials, and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.

CONTACT: For further information on Transition, visitwww.transitiontherapeutics.com or contact: Dr. Tony Cruz, Chief ExecutiveOfficer, Transition Therapeutics Inc., Phone: (416) 260-7770, x.223,; Mr. Elie Farah, CFO and VP, CorporateDevelopment, Transition Therapeutics Inc., Phone: (416) 260-7770, x.203, tcruz@transitiontherapeutics.com efarah@transitiontherapeutics.com

Ticker Symbol: (Toronto:TTH.)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:10/9/2008)...cted in November 2008, BOTHELL, Wash., Oct. 9 /PR...DDD ) announced today the completion of patient en...otal trials to evaluate the safety and,efficacy of...ibuprofen for,the over-the-counter (OTC) market. T... this pivotal trial in November 2008. Ibuprofen is...
(Date:10/8/2008)...swire-USNewswire/ -- The facts are,overwhelming. E...,sub-Saharan Africa. More than 35,000,000 women, c...y died of AIDS. The Foundation for Hospices,in Sub... their families,find compassion and relief from su...tnering initiative links African hospices and pall...
(Date:10/8/2008)...rs Research That May Offer New Hope to,Heart Failu...onally, over 3,000 people are,waiting for a heart ...half,of those will receive a transplant. Now, pion...s paving the way for how to treat congestive heart...News Release, go to:, http://www.prnewswire.com/mn...
(Date:10/8/2008)...te TAXUS(R) Element(TM) Platinum Chromium .... 8 /- Boston Scientific,Co...s completed enrollment in,the PERSEUS trial, desig...US(R) Element(TM) paclitaxel-eluting coronary sten...y 1,500 patients at 100 U.S. and,international cen...
Breaking Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4New Water Purification Product from Reliance Products and Procter 26 Gamble now Available in Retail Stores 11932 1New Water Purification Product from Reliance Products and Procter 26 Gamble now Available in Retail Stores 11932 2New Water Purification Product from Reliance Products and Procter 26 Gamble now Available in Retail Stores 11932 3LodgeNet Interactive Corporation 2007 Earnings Release and Teleconference Announcement 11927 1LodgeNet Interactive Corporation 2007 Earnings Release and Teleconference Announcement 11927 2Rural Hospital Chooses Microsoft Dynamics GP for Healthy Time and Labor Savings 11925 1Rural Hospital Chooses Microsoft Dynamics GP for Healthy Time and Labor Savings 11925 2Rural Hospital Chooses Microsoft Dynamics GP for Healthy Time and Labor Savings 11925 3Rural Hospital Chooses Microsoft Dynamics GP for Healthy Time and Labor Savings 11925 4NIH report on intracranial stent points out need for upcoming large scale clinical trial 11921 1NIH report on intracranial stent points out need for upcoming large scale clinical trial 11921 2
...e 07, 2007 /PRNewswire-FirstCall/ -,Neurochem (Int...bsidiary of Neurochem Inc. , announces that the Ne... results of the "Eprodisate,For AA Amyloidosis Tri...al in the search for a treatment of AA amyloidosis...or eprodisate,(KIACTA(TM)) demonstrate that this p...
...zonisamide SR as a novel component in,EMPATIC(TM) .../PRNewswire-FirstCall/ -- Orexigen(TM),Therapeutic...he,treatment of central nervous system disorders w...esults from a Phase I trial evaluating,safety and ...ned-release (SR) formulation of zonisamide. In the...
Other Medicine Technology:Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 2Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 3Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 4Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 5OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
(Date:10/10/2008)...1 in 6 likely to develop some form of disease by 2...FRIDAY, Oct. 10 (HealthDay News) -- Liver transpla... the general population, say researchers in Finlan...ssue of Liver Transplantation , researchers inves...er transplant recipients from Helsinki University ...
(Date:10/10/2008)... Eli Lilly and Company committed to helping peop...RNewswire-FirstCall/ -- In these troubling,economi...care a priority,and may feel that they don,t have ...tion. According to a survey by the National Associ...n August 2008:(1), -- Twenty-two percent of Ameri...
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... Topics range from bullyi... Boston (Vocus) October 10, 2008 -- S... Medical Center will be presenting at the 2008 Am...nd Exhibition, which runs from October 11 - 14 in ..., Pediatrician Dana Best, MD, MPH, will present ...
Breaking Medicine News(10 mins):Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Children's National Experts Presenting at American Academy of Pediatrics Conference 2
...tal management to offer a pay of nearly $500,000 t...ponse to the above proposal, the Queensland Opposi...onscionable. The popular Aspen Medical Group had ...or for the emergency medicine department, with an ...
...ls in sub-Saharan Africa have joined forces to cre... allow vets// to study for postgraduate degrees wh...Veterinary E-Learning Consortium, launched in earl...vets unable to attend full-time degrees, reported ...
...run all educational and charitable institutions op...istian mission whose head was // detained in conne... and maintains schools, hospitals and orphanages i...ent earlier this month had cancelled the registrat...
...opment Minister today in New Delhi Announced that ...e status under the governments // Total Sanitation...roblem that is not faced only in rural India but a... public bathrooms, a clean sanitation environment,...
Other Medicine News:Health News:Rajasthan Plans To Run Christian Institutions 2Health News:India On The Road To Become 'Open Defecation Free' 2
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: